Peter and Dan discuss takeaways from Abundance 360, Peter’s executive summit where four rockstar longevity CEOs summarized new capabilities in the healthcare industry. These cutting-edge companies, whose early experiments have produced amazing results, will have therapies and drugs on the market in the next one to five years.

In this episode:

Peter mentions Mark Allen, the CEO of Elevian, on the “young blood” research he’s commercializing. He also explains the research and early stage experiments to give GDF11 to humans in the next five years.

The second company mentioned is Celularity, where CEO Bob Hariri, a pioneer in the stem cell business, has developed the best stem cells available to help rejuvenate the regenerative engine in your body.

The next company is Unity Biosciences, a company backed by Jeff Bezos. This company has created the ability to identify and kill senescent cells, and are entering human trials in the next five years.

The final company is Samumed, and its CEO Osman Kibar. Peter explains the company’s miraculous mission to regrow cartilage to a youthful state with a single injection and its wrinkle-eliminating cream.